Aortic Aneurysm, Thoracic Clinical Trial
— RelayPro-AOfficial title:
A Prospective, Multicenter, Non-Blinded, Non-Randomized Study of the RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers
Verified date | November 2023 |
Source | Bolton Medical |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Investigate the safety and effectiveness of the RelayPro Thoracic Stent-Grafts in subjects with thoracic aortic aneurysms (TAA) and penetrating atherosclerotic ulcers (PAU) of the descending thoracic aorta.
Status | Active, not recruiting |
Enrollment | 110 |
Est. completion date | June 2024 |
Est. primary completion date | June 24, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject must be = 18 years of age - Subject has specified disease in his/her descending thoracic aorta. - Subject have anatomical compliance for the device specified for both access vessels and treatment area. - Subject must be willing to comply with the follow-up evaluation schedule. - Subject (or Legally Authorized Representative) agrees an Informed Consent Form prior to treatment. Exclusion Criteria: - Subject has specified disease of the thoracic aorta which is not included in the trial, for example: aortic dissection, intramural hematoma, traumatic injury or transection, aortic false aneurysm, ruptured aneurysm. - Subject anatomy with significant stenosis, calcification, thrombus or tortuosity. - Subjects with specified compromised circulation. - Subjects with specified prior procedures. - Subjects with allergy to contrast media or device components. - Subjects with disease, for example: suspected connective tissue disorder, specified coagulation disorders, specified coronary artery disease, severe congestive heart failure, stroke and/or Myocardial Infarction (MI) as specified, specified pulmonary disease, specified renal failure. - Subjects that are pregnant or planning to become pregnant during the course of the study. |
Country | Name | City | State |
---|---|---|---|
Japan | Hiroshima University Hospital | Hiroshima | |
Japan | Morinomiya Hospital | Joto-ku | Osaka |
Japan | Nara Medical University Hospital | Kashihara | Nara |
Japan | Jikei University Hospital | Minato-Ku | Tokyo |
Japan | Nagoya University Hospital | Nagoya | Aichi |
Japan | Niigata University Medical & Dental Hospital | Niigata City | Niigata |
Japan | Jichi Medical University Saitama Medical Center | Omiya | Saitama |
Japan | Teine Keihinkai Hospital | Sapporo | Hokkaido |
Japan | Keio University Hospital | Shinjuku-Ku | Tokyo |
Japan | National Cerebral & Cardiovascular Center | Suita | Osaka |
Japan | Oita University Hospital | Yufu City | Oita |
United States | University of Michigan | Ann Arbor | Michigan |
United States | Emory University | Atlanta | Georgia |
United States | University of Alabama-Birmingham | Birmingham | Alabama |
United States | Beth Israel Deaconess Medical Center / Harvard Medical School | Boston | Massachusetts |
United States | Tufts Medical Center | Boston | Massachusetts |
United States | Cleveland Clinic Foundation | Cleveland | Ohio |
United States | University Hospitals | Cleveland | Ohio |
United States | University of Texas Southwestern | Dallas | Texas |
United States | University of Florida | Gainesville | Florida |
United States | Hartford Hospital | Hartford | Connecticut |
United States | Indiana University Health | Indianapolis | Indiana |
United States | St. Vincent Heart Center | Indianapolis | Indiana |
United States | University of Iowa Hospital and Clinic | Iowa City | Iowa |
United States | University of California, Irvine | Irvine | California |
United States | Long Beach Memorial Hospital | Long Beach | California |
United States | Centennial Heart & Vascular Institute Sarah Cannon Research Institute | Nashville | Tennessee |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Newark Beth Israel Medical Center | Newark | New Jersey |
United States | University of Pennsylvania Medical Center / Penn Presbyterian | Philadelphia | Pennsylvania |
United States | Arizona Heart Institute | Phoenix | Arizona |
United States | Baylor Scott & White Medical Center - Plano The Heart Hospital | Plano | Texas |
United States | Baystate Medical Center | Springfield | Massachusetts |
United States | Baylor Scot & White Medical Center - Temple | Temple | Texas |
United States | Lankenau Medical Center | Wynnewood | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Bolton Medical |
United States, Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of Major Adverse Events (MAEs) | Primary safety endpoint is a composite of the following MAEs occurring through 30 days:
Death Stroke (excluding transient ischemic attack) Paralysis (excludes paraparesis) |
30 days | |
Primary | Technical success | Primary effectiveness rate as measured by the technical success through 24 hours, defined as:
Successful delivery of the device through the vasculature; Successful deployment of the device at the intended location; Absence of Type I or III endoleaks; Patent stent-graft without significant stenosis. |
24 hours | |
Primary | Stent graft patency | Primary effectiveness as measured by the rate of stent-graft patency through 12 months. | 12 months | |
Primary | Aneurysm rupture | Primary effectiveness as measured by the absence of aneurysm rupture through 12 months. | 12 months | |
Primary | Absence of Type I and III endoleak through 12 months; | Primary effectiveness as measured by the absence of Type I and III endoleak through 12 months. | 12 months | |
Primary | Absence of stent fractures in the attachment zone through 12 months | Primary effectiveness as measured by the absence of stent fractures in the attachment zone through 12 months. | 12 months | |
Primary | Absence of open or endovascular secondary interventions | Primary effectiveness as measured by the absence of open or endovascular secondary interventions related to the device or treated pathology through 12 months. | 12 months | |
Primary | Absence of aneurysm expansion (> 5 mm diameter increase) | Primary effectiveness as measured by the absence of aneurysm expansion (> 5 mm diameter increase) through 12 months, compared to the first post-procedural computed tomographic (CT) imaging study. | 12 months | |
Primary | Absence of stent-graft migration | Primary effectiveness as measured by the absence of stent-graft migration (> 10 mm) through 12 months, compared to the first post-procedural CT. | 12 months | |
Secondary | Loss of stent-graft patency | Loss of stent-graft patency will be assessed with CT scans, or MRIs for subjects unable to tolerate contrast media. | 1 month and 6 months | |
Secondary | Rate of aneurysm rupture | The rate of aneurysm rupture through 1 month and 6 months will be assessed by review of CT or MRI imaging, in addition to site reported adverse events. | 1 month and 6 months | |
Secondary | Rate of endoleaks of all types | Persistence of blood flow outside the lumen of the stent-graft but within the native aorta or adjacent vascular segment being treated by the stent-graft will be assessed by CT scans or MRIs for subjects unable to tolerate contrast media. | 1 month, 6 months and 12 months | |
Secondary | Rate of stent fractures in the attachment zone | Stent fractures in the attachment zone will be assessed at each follow-up visit with CT scans, or MRIs for subjects unable to tolerate contrast media. | 1 month and 6 months | |
Secondary | Incidence of open or endovascular secondary interventions | Secondary effectiveness will be measured by the incidence of open or endovascular secondary interventions related to the device or treated pathology (ie, interventions to treat malperfusion, rupture, aneurysm formation, or aortic expansion). | 1 month and 6 months | |
Secondary | Rate of aneurysm expansion | The rate of aneurysm expansion (> 5 mm diameter increase) assessed by comparison of follow-up imaging to the first post-procedural CT | 1 month and 6 months | |
Secondary | Rate of stent-graft migration | The rate of stent-graft migration (> 10 mm) assessed by comparison of follow-up imaging to the first post-procedural CT. | 1 month and 6 months | |
Secondary | Individual outcomes of composite MAEs | Secondary effectiveness as measured by the individual outcomes of the composite safety endpoints (death, stroke, paralysis), as well as myocardial infarction (MI), renal failure, respiratory failure, bowel ischemia, and procedural blood loss >1,000 cc. | 6 months and 12 months | |
Secondary | Rate of vascular access complications | Secondary effectiveness as measured by the rate of vascular access complications reported during the Treatment visit (stent-graft implant). Outcome measures include successful delivery and deployment of the device, as well as withdrawal of the delivery system. | During the initial implant attempt | |
Secondary | Duration of implant procedure | Duration of the initial implant procedure captured as the number of minutes from introduction of device to removal of delivery system. | Treatment Visit | |
Secondary | Number of blood transfusions | Number of transfusions (units) required from the time of implant through hospital discharge. | Treatment Visit through Discharge Visit | |
Secondary | Duration of hospitalization | Length of hospital stay defined as number of days subject was hospitalized for the initial implant procedure. | Treatment Visit through Discharge Visit | |
Secondary | Time in Intensive Care Unit (ICU) | Duration of time in hours that subject was admitted to the Intensive Care Unit (ICU) following the implant procedure. | Treatment Visit through Discharge Visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02777593 -
Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2
|
N/A | |
Completed |
NCT02876263 -
Noninvasive Neuromonitoring of Surgery of the Thoracic Aorta
|
N/A | |
Terminated |
NCT02538822 -
Risk of Rupture of Aneurysms of the Thoracic Ascending Aorta (ATA) From the Dynamic Imaging
|
N/A | |
Completed |
NCT04930172 -
TOtal tRansfemoral branCHed endovasCular tHoracoabdominal Aortic Repair Registry
|
||
Completed |
NCT03207568 -
RE-GENERATION: The Safety and Performance of the Relay Pro and Relay NBS Pro Stent-graft Devices in the European Union (EU)
|
N/A | |
Recruiting |
NCT03010514 -
A Registry Study on Genetics and Biomarkers of Thoracic Aortic Aneurysm/Dissection
|
N/A | |
Completed |
NCT02266342 -
GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry
|
||
Completed |
NCT00757003 -
To Evaluate the Safety and Efficacy for GORE TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Disease
|
Phase 3 | |
Recruiting |
NCT03574311 -
Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Cardiac Surgery
|
Phase 4 | |
Suspended |
NCT03410420 -
Detection of Hypoxia in Human Thoracic Aorta Using Pimonidazole Hydrochloride
|
Phase 1 | |
Recruiting |
NCT05703893 -
Investigation of the Neurovegetative Pattern in Patients With Thoracic Aortic Aneurysms (TAA)
|
||
Enrolling by invitation |
NCT05800743 -
Evaluation of the GORE® Ascending Stent Graft
|
N/A | |
Completed |
NCT02253082 -
Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28)
|
Phase 4 | |
Recruiting |
NCT02323581 -
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
|
N/A | |
Active, not recruiting |
NCT03414866 -
Thoraflex Hybrid Post-Market Study
|
||
Recruiting |
NCT01985906 -
Safety and Efficacy of Multiple Overlapping Uncovered Stents for Pararenal Aortic Aneurysm Repair
|
N/A | |
Completed |
NCT03479164 -
Development of Ultra-Low Dose CT Based Screening for Aortic Aneurysms
|
N/A | |
Completed |
NCT01775046 -
Valiant Thoracic Stent Graft With the Captivia Delivery System in the Treatment of Descending Thoracic Aortic Diseases (VALIANT CAPTIVIA France)
|
||
Recruiting |
NCT04814238 -
Minimally Invasive Aortic Root and Aorta surGery rEgistry
|
||
Completed |
NCT01756911 -
Evaluation of the Safety and Efficacy of the Multilayer Stent
|
N/A |